What the FDA labels say about taking them together
Drospirenone/ethinyl estradiol and ritonavir
Drospirenone/ethinyl estradiol's FDA label of May 29, 2025 names ritonavir in its contraindications section; the ritonavir label PlainMeds reads does not name drospirenone/ethinyl estradiol. The drospirenone/ethinyl estradiol label: “Use with HCV Combination Therapy – Liver Enzyme Elevation Do not co-administer Yasmin with HCV drug combinations containing ombitasvir/paritaprevir/ritonavir, with or without dasabuvir, due to potential for ALT …”
Check it at the source: the drospirenone/ethinyl estradiol FDA label on DailyMed (effective May 29, 2025, Bayer HealthCare Pharmaceuticals Inc.); the ritonavir FDA label on DailyMed (effective July 23, 2026, AbbVie Inc.).
What does the drospirenone/ethinyl estradiol label say about ritonavir?
Drospirenone/ethinyl estradiol label, contraindicationsUse of Hepatitis C drug combinations containing ombitasvir, paritaprevir/ritonavir, with or without dasabuvir due to the potential for ALT elevations [see Warnings and Precautions ( 5.5 ) and Drug Interactions ( 7.3 )].
Drospirenone/ethinyl estradiol label, drug interactionsUse with HCV Combination Therapy – Liver Enzyme Elevation Do not co-administer Yaz with HCV drug combinations containing ombitasvir/paritaprevir/ritonavir, with or without dasabuvir, due to potential for ALT elevations [see Warnings and Precautions ( 5.5 )].
Drospirenone/ethinyl estradiol label, warnings and precautionsElevations with Concomitant Hepatitis C Treatment During clinical trials with the Hepatitis C combination drug regimen that contains ombitasvir/paritaprevir/ritonavir, with or without dasabuvir, ALT elevations greater than 5 times the upper limit of normal (ULN), including some cases greater than 20 times the ULN, were significantly more frequent in women using ethinyl estradiol-containing medications, such as COCs.
Source: FDA drug label (Yasmin, NDA021098), Bayer HealthCare Pharmaceuticals Inc., effective May 19, 2023 (SPL set d7ea6a60-5a56-4f81-b206-9b27b7e58875), via openFDA
Source: FDA drug label (Yaz), Bayer HealthCare Pharmaceuticals Inc., effective May 29, 2025 (SPL set 065f33e4-b587-4e66-b896-ca9ab7b7c876), via openFDA; the full label on DailyMed
What does the ritonavir label say about drospirenone/ethinyl estradiol?
Ritonavir's label (effective July 23, 2026) does not name drospirenone/ethinyl estradiol in these sections. A label lists what its studies and reports found; it is not a complete list.
Source: FDA drug label (Norvir), AbbVie Inc., effective July 23, 2026 (SPL set 2849298e-de6e-47bb-8194-56e075b33fc3), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Drospirenone/ethinyl estradiol | Ritonavir | |
|---|---|---|
| Labeled for | Acne, Birth control | HIV |
| Boxed warning | Yes | Yes |
| Pharmacy cost (NADAC) | $0.151 per tablet 3-0.03 mg tablet | $0.607 per tablet 100 mg tablet |
| Shortage now | No current entry | A presentation being discontinued |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once